What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

This research investigates the use of an LLM-based system for screening patient eligibility in clinical trials for polycythemia vera.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

This research investigates the use of an LLM-based system for screening patient eligibility in clinical trials for polycythemia vera.
A randomized phase 3 study comparing givinostat versus hydroxyurea was conducted.
Synapsis AI pre-screened patients using structured and unstructured data from medical records.
Eligibility was assessed against specific inclusion and exclusion criteria using artificial intelligence.
Out of 4.7 million EMRs, 28,200 patients with oncology diagnoses were identified, with 904 having polycythemia vera.
Synapsis AI identified 22 eligible patients within one week with 100% positive predictive value.
Traditional methods found only 9 potential candidates, treating 3 over a year, highlighting Synapsis AI's 7-fold increase in efficiency.

No takes yet. Share an insight, caveat, or question.

Artificial intelligence enhances trial recruitment efficiency, identifying eligible patients faster in rare diseases like polycythemia vera.

Vecchio et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Artificial intelligence enhances trial recruitment efficiency, identifying eligible patients faster in rare diseases like polycythemia vera.